BioBusiness

Aging populations and increased access to healthcare translates into opportunities for biopharmaceutical companies. JLL’s 2015 Life Sciences Outlook report highlights global clusters worth watching.

This article examines trends in biopharma post-grant patent review and projects what the future holds in store.

Aging populations and increased access to healthcare translates into opportunities for biopharmaceutical companies. JLL’s 2015 Life Sciences Outlook report highlights global clusters worth watching.

How can the industry achieve excellence when its training programs are geared to meeting minimum regulatory guidelines?

In the development of biopharmaceuticals and pharmaceuticals, the line is blurring.

China’s emergence as a significant commercial market is forcing manufacturers to re-evaluate their overall business model.

European Union regulators said Pfizer must divest its infliximab biosimilar candidate and some sterile injectables for the merger with Hospira to be completely approved.

FDA notes progress in drug development, but cites scientific and funding roadblocks.

The 21st Century Cures Act took a giant step forward with a 344-77 approval in the House; the Senate debate is still ahead.

As biopharma enjoys success, it cannot ignore pressing patient access questions.

Jim Miller, President of PharmSource, speaks with BioPharm International.

Eric Langer, Managing partner at BioPlan Associates, speaks with BioPharm International about emerging trends in cell therapy.

If adopted, open innovation, beyond outsourcing and licensing, could boost biopharm pipelines four-fold, a recent Deloitte study suggests.

EvaluatePharma report shows continued pharma and biotech sector confidence.

Important IP contractual provisions should be included when working with CMOs.

As the biopharma industry awaits FDA’s guidance on biosimilar naming, brand and generic manufacturers establish positions.

The method patent covers the infusion of bendamustine hydrochloride for the treatment of certain blood cancers.

Supply chain consortium establishes a working group to address quality problems in India.

The Australian pharmaceutical market offers opportunities for manufacturers despite challenges.

 jayk7/Getty Images

Mallinckrodt Pharmaceuticals has bought Ikaria, a privately-held critical care company, for $2.3 billion.

Changes in the country’s political landscape may affect the pharmaceutical industry market in the future.

Investors are lining up for the biosimilars market as patents reach expiration and regulatory pathways are defined.

Manufacturers are under pressure to develop pipelines, promote quality, and justify pricing.

Although competing therapies will continue to be released in the immune-oncology space, efficacy profiles, combination regimens, and administration setting may influence a drug’s preferred status more than price.